Table 2.
Treatment outcomes
| Most recent prior therapy |
Patient number |
Best response |
Disease progression |
PFSa (months) |
Deathb | OSa (months) |
Follow-upa (months) |
|---|---|---|---|---|---|---|---|
| TKIc | 1 | PR | Yes | 15 | Yes | 17 | 17 |
| 2 | SD | Yes | 6 | Yes | 11 | 11 | |
| 3 | SD | Yes | 6 | Yes | 9 | 9 | |
| ICI | 4 | PR | Yes | 9 | Yes | 9 | 9 |
| 5 | PR | Yes | 3 | No | 11+ | 11+ | |
| 6 | PD | Yes | 3 | Yes | 4 | 4 | |
| 7 | SD | Yes | 9 | No | 9+ | 9+ |
a
A conversion factor of 30.4375 was used to convert number of days into months; patients who were still alive at last follow-up (October 29, 2019) are indicated with a plus for OS as survival is ongoing at the time of manuscript preparation.
b
Patient’s survival status as of last follow-up (October 29, 2019).
c
Patient 2 received lenvatinib plus nivolumab (TKI + ICI) as last prior therapy.
ICI, immune checkpoint inhibitor; OS, overall survival; PFS, progression-free survival; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.